cyrilzakka/clinical-trials huggingface dataset:
4% Chlorhexidine Gluconate Daily Bathing for Prevention of Hospital-acquired Infections in Intensive Care Settings

The study will assess the utility of 4% chlorhexidine gluconate (CHG) daily bathing to reduce hospital acquired infections in patients admitted to intensive care units. One group will be daily bathed with 4% CHG and the other group with standard soap.


Eligibility Criteria:
Inclusion Criteria:

* admission to the intensive care unit (ICU) or to the post-operative cardiosurgical ICU (PC-ICU)
* ICU/PC-ICU stay for at least 1 night

Exclusion Criteria:

* known allergy to chlorhexidine
* burns, toxic epidermal necrolysis or Stevens-Johnson syndrome as admission diagnosis
* pregnancy
Hematopoietic Stem Cell Transplant for Fanconi Anemia

The trial proposed is a single arm phase II treatment protocol designed to examine engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine and anti-thymocyte globulin (ATG- a non-chemotherapy drug whose role is to kill your immune system) for the treatment of patients with Fanconi anemia who have severe aplastic anemia (SAA), or myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), lacking HLA-genotypically identical donors using stem cell transplants derived from (1) HLA-compatible unrelated donors or (2) HLA haplotype-mismatched related donors.

We are currently recruiting patients.

Eligibility Criteria:
Inclusion Criteria:

* Fanconi Anemia (confirmed by mitomycin C or DEB chromosomal breakage testing and one of the following hematological diagnoses: Severe Aplastic Anemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia
* Karnofsky or Lansy performance scale \> or = to 70%.
* Must have adequate cardiac, hepatic, renal and pulmonary function.
* Must have 7/8 or 8/8 available unrelated donor.

Exclusion Criteria:

* Pregnant or breastfeeding.
* Active CNS leukemic involvement
* Active uncontrolled viral, bacterial or fungal infection
* Positive for HIV.
Syncope-Asystole Latency Time in Tilt Table Test: The SALT-TILT Study

Syncope is a common presenting condition. Pacemaker implantation can significantly reduce syncope recurrences in reflex syncope. However, despite careful selection, a substantial proportion of patients treated with pacemakers suffer recurrences of syncope. It is thought that a pronounced vasodepressor component may hinder the efficacy of pacing in patients, preventing adequate cerebral perfusion during the reflex, thus relativizing the anti-bradycardia function of the pacemaker to prevent syncope. It is hypothesised that the time elapsed from the actual loss of consciousness to the asystole recorded on the ECG during Tilt Table Test may be predictive in terms of response to pacemaker therapy, so this parameter becomes the subject of the present study.

Syncope is a common leading affection and is responsible for 1-3% of the presentations in emergency departments and up to 3% of inpatient admissions. Syncope poses often a diagnostic and therapeutic challenge for the attending physician and is often misdiagnosed or underdiagnosed. Patients can be treated with pacemaker implantation when the syncope cause is a cardioinhibition with documented asystole during the syncopal event. When accurately selected, patients benefit from pacemaker therapy with a significant reduction of syncope recurrence in the follow up. However, a substantial portion of the patients (approx. 25%) experience recurrence of syncope despite optimal pacemaker therapy. The underlying mechanism is not well understood and object of the current study.

The main target of the study is to evaluate the time elapsed between the T-LOC during Video Tilt Table Testing and the asystole at the ECG using a registry and to assess its predictive value in patients undergoing invasive treatment. The hypothesis is that a vasodepressive component could lessen the effect of pacing in a patient, leading to cerebral hypoperfusion and syncope despite maintaining a stable rhythm.

This is a prospective, multi-center observational study with 2 year follow-up of patients. Patients eligible for invasive treatment of reflex syncope are included.

If after guideline-directed implantable loop recorder insertion no cardioinhibition has been recorded, the patient is included automatically in the registry.

Eligibility Criteria:
Inclusion Criteria:

* Patients eligible for invasive treatment according to the ESC Guidelines for pacing 2021
* Written informed consent

Exclusion Criteria:

* Other condition which explains syncope cause other than reflex syncope
* Structural heart disease (valvular, ischaemic, cardiomyopathies)
* Pregnancy
* Patient denial to be recorded on video during tilt table test
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.


Eligibility Criteria:
Inclusion Criteria:

* Participants must have a Body Mass Index (BMI) ) ≥30 and ≤50 kilograms per square meter (kg/m²), or ≥27 kg/m² and \<30 kg/m², with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease
* Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires

Exclusion Criteria:

* Participants must not have type 1 or type 2 diabetes mellitus
* Participants must not have had an increase or decrease in body weight \> more than 5 kg (11 pounds) within the past 3 months
* Participants must not have had surgery for obesity or plan to have such surgery during the study
* Participants must not be using medications that promote weight loss or cause weight gain
* Participants must not drink excessive amounts of alcohol (more than 14 units a week for women or more than 21 units a week for men)
* Participants must not have used marijuana within the last 3 months.
* Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months
* Participants must not have active cancer within the last 5 years
* Participants must not have uncontrolled high blood pressure
* Participants must not have liver disease other than non-alcoholic fatty liver disease
* Participants must not have renal impairment with estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m2
* Participants must not have a history of acute or chronic pancreatitis symptomatic gallbladder disease or documented human immunodeficiency virus infection
* Participants must not have a major problem with depression or other mental illness within the last 2 years
* Participants must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)
* Female participants must not be pregnant, breast-feeding, or intend to become pregnant or of childbearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

This trial is conducted in Africa, Asia, Europe and the United States of America (USA).

The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with type 2 diabetes. Treatment will be added onto subject's pre-trial background diabetes treatment of either diet and exercise only or single compound oral antidiabetic drug (OAD) treatment (metformin, sulphonylurea \[SU\] or glitazone) or combination OAD treatment (metformin, sulphonylurea or glitazone). The duration of the trial will be 56 weeks followed by a 12 week observational follow-up period.


Eligibility Criteria:
Inclusion Criteria:

* Informed consent obtained
* Subjects diagnosed with type 2 diabetes and treated with either diet and exercise alone, metformin, sulphonylurea, glitazone as single agent therapy or a combination of the previously mentioned compounds
* HbA1c 7.0-10.0% (both inclusive)
* Body Mass Index (BMI) at least 27.0 kg/m\^2
* Stable body weight
* Preceding failed dietary effort

Exclusion Criteria:

* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors or insulin within the last 3 months
* Known proliferative retinopathy or maculopathy
* History of acute or chronic pancreatitis
* Obesity induced by drug treatment
* Use of approved weight lowering pharmacotherapy
* Previous surgical treatment of obesity
* History of major depressive disorder or suicide attempt
* Uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)
* Screening calcitonin of 50 ng/L or above
* Familial or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
* Personal history of non-familial medullary thyroid carcinoma
PHA-739358 for the Treatment of Multiple Myeloma

The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.


Eligibility Criteria:
Inclusion Criteria:

* active multiple myeloma progressing after at least 2 prior lines of treatment
* measurable disease
* t(4;14) translocation
* life expectancy of at least 3 months

Exclusion Criteria:

* uncontrolled hypertension
* myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months.
* pregnancy or breast feeding
* active infections, including HIV
Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction Monitoring

The SPARK trial is testing the use of Kilovoltage Intrafraction Monitoring in prostate cancer patients being treated with Stereotactic Prostate Adaptive Radiotherapy. The researchers expect this trial to result in better targeted prostate cancer patient outcomes with lower toxicity. The potential application of Kilovoltage Intrafraction Monitoring to other tumour sites will pave the way for additional trials with Australasian radiation oncology leading the world.

Most linear accelerators used to treat cancer patients today are equipped with fixed X-ray imagers which are typically used to take images of a tumour before a patient receives radiotherapy. A new technology, known as Kilovoltage Intrafraction Monitoring has recently emerged which allows images of a tumour to be taken in real-time while the treatment is occurring. The advantage of Kilovoltage Intrafraction Monitoring is that it enables strategies such as patient shifting or beam shifting during treatment which could potentially improve the accuracy of the treatment and reduce the patient's side effects. In addition, due to the accuracy of Kilovoltage Intrafraction Monitoring in targeting tumours, the number of treatment sessions this group of patients will require will be reduced to five as opposed to the 40 sessions required using more conventional treatment methods.

Eligibility Criteria:
Inclusion Criteria:

1. Histologically proven prostate adenocarcinoma
2. Low or intermediate risk disease as defined by:

   * Low Risk: All of PSA\<10 ng/mL, Gleason Grade 6 AND Stage T1 or T2a
   * Intermediate Risk: Any or all of PSA 10-20 ng/mL, Gleason Grade 7 OR Stage T2b-c
   * Absence of high risk features (PSA\>20, T3-4, N1 or M1 disease, Gleason score 8-10) (PSA must be within 3 months prior to enrolment)
3. ECOG Performance status 0-2
4. Suitable for definitive external beam radiotherapy (IMRT or VMAT)
5. Ability to have three gold fiducial markers placed in the prostate
6. Six month course of androgen deprivation therapy allowed at clinician discretion.
7. Available for follow up for a minimum of 2 years (up to 3 years)

Exclusion Criteria:

1. Lymph node irradiation
2. Any other systemic anti-prostate cancer therapy (i.e. non-ADT) both proven in the metastatic setting and investigational (e.g. docetaxel, enzalutamide)
3. Artificial hip(s) (Unable to visualise markers through prosthesis)
4. Prostate volume \> 90 cm3 measured from the CT scan
5. Patient lateral dimension \>40cm as measured at the level of the prostate from the CT scan
6. Suboptimal fiducial markers placement for treatment utilising KIM as assessed by a medical physicist by measuring marker positions from the CT scan
7. Fiducial migration or fewer than 3 fiducials present in the CT scan
Arthroscopic Treatment of Meniscal Lesions on Healthy Meniscus in Children and Adolescents

Meniscal lesions are common in pediatrics and mainly affect adolescents. These lesions can jeopardize the functional prognosis of the knee in the short, medium or long term if they are not well managed.

More precisely, it is a question of determining whether arthroscopic repair of isolated meniscal lesions in children gives good results and what factors influence them, with the aim of improving the care of children suffering from meniscal lesions.

The treatment of meniscal lesions comes down to either conservative or restorative treatment or non-conservative treatment by meniscectomy. For most authors, the treatment of meniscal lesions must remain restorative through meniscal suture, leaving no room for meniscectomy. The open approach has given way to the arthroscopic approach which, according to the literature, is the gold standard. Meniscal lesions are varied and therefore there are numerous therapeutic procedures. Therapeutic indications are precise but the results of the treatments remain differently assessed depending on the studies; studies evaluating the results of treatment in the pediatric population are few in number.

Based on this observation, the present study aims to describe the results of repairs of meniscal lesions in pediatric traumatology.


Eligibility Criteria:
Inclusion Criteria:

* Minor subject under 18 years old
* Subject operated on at Strasbourg University Hospital for repair of lesions on healthy meniscus during the period from February 1, 2010 to September 30, 2022.
* Absence of written opposition in the medical file of the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.

Exclusion Criteria:

* Presence of opposition from the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.
* Subject with lesion on discoid meniscus
* Incomplete or unusable clinical file
Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

The purpose of this study is to determine whether moxonidine is effective in reducing urine albumin levels in patients with diabetic kidney disease.

This study will investigate the effect of moxonidine in lowering urine albumin excretion and limiting further damage to the kidneys in patients with diabetic nephropathy. Reducing urine albumin excretion in type 2 diabetic patients is an indicator of successful treatment. Previous studies have shown that drugs that work in a similar fashion to moxonidine (intervene with the sympathetic nervous system)have been very effective in reducing the amount of albumin in the urine and are associated with long term renal and cardiovascular protection.

Eligibility Criteria:
Inclusion Criteria:

* age: 18-75 years
* diabetic nephropathy as defined by the mean of three consecutive early morning urinary albumin-creatinine ratios (UACR) of \>300mg per gram, or \> 200mg per gram in patients receiving therapy targeted at blockade of the RAS

Exclusion Criteria:

* non-diabetic kidney disease
* UACR of more than 3500mg per gram, an estimated glomerular filtration rate of less than 30ml/min/1.73m2.
* chronic urinary tract infection.
* severe hypertension
* heart failure New York Heart Association (NYHA) class II-IV
* major cardiovascular disease within the previous 6 months
* left ventricular ejection fraction \<55%
Ivermectin In Treatment of COVID 19 Patients

as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

the study will compare the effect of ivermectin in comaprison and addition to the standard mode of care for the COVID 19 patients

Eligibility Criteria:
Inclusion Criteria:

* Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral RNA swap

Exclusion Criteria:

* Contraindications for the drug: hypersensitivity.
* Any medications with possible drug interactions.
* Severe cases.
* Any malignant condition.
* Pregnant females.
* Breast feeding females.
* Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.
To Compare the Efficacy and Patients' Satisfaction for the Treatment of Post Cesarean Pain of Two Protocols: Oral Medications in Fixed Time Interval Administration Versus Spinal Morphine

Cesarean deliveries are prevalent. Unlike other operations, quick recovery is required for the mother to nurture the newborn child and establishing an appropriate mother-child bonding.

Cesarean deliveries are prevalent. Unlike other operations, quick recovery is required for the mother to nurture the newborn child and establishing an appropriate mother-child bonding. Therefore, effective pain management is crucial. In this study we would like to compare between two pain relievers' administration protocols:

1. Oral pain relievers' administration in fix protocol without need for patient demand
2. Spinal morphine given during the spinal anesthesia in the cesarean section

Eligibility Criteria:
Inclusion Criteria:

* women that underwent cesarean section with sinal anesthesia

Exclusion Criteria:

* Women who suffer from chronic pain
* Women using chronic pain medications
* Women with allergy to any drug used in the study
* Women underwent general anesthesia during the surgery
* Women who suffer from sleep apnea
* Women who suffer from obesity (BMI\>40)
* Women who suffer from severe nausea and vomiting after previous surgery
* Women who received perioperative magnesium
* Women who suffer from hypertension
* Women who suffer from renal failure
Does the Natural Medicinal Plant St John's Wort Affect the Glucose Tolerance in Healthy Individuals

The goal of the study is to examine if healthy individuals that ingest St John's wort will have a significantly difference in glucose tolerance.


Eligibility Criteria:
Inclusion Criteria:

* 18-40 years
* Males
* Fasting plasma-glucose \< 7.0 mmol/L
* Glycosylated haemoglobin A1c within reference or clinically insignificant deviation hereof
* Body mass index \< 30 kg/m\^2

Exclusion Criteria:

* Hypersensitivity to St John's wort
* Chronical or daily alcohol abuse
* Known liver disease
* Ingestion of drugs requiring prescription, except locally acting drugs
Accuracy of Upper Lip Bite Test and Measurement of Skin-to-epiglottis Distance in Predicting Difficult Laryngoscopy: a Prospective Observational Study

Airway management is one of the most important skills in everyday practice of anesthesia. Improper airway management might lead to high risk of mortality. clinical parameters alone cannot predict all potentially difficult airways. Ultrasonography (US) might play a role as a potential screening tool for difficult airway and given the limited empirical study in this field; this research will focus on using ultrasound to predict difficult airway and difficult mask ventilation for patients undergoing elective operation under general anesthesia. Methodology This study is Prospective observational . The study will be conducted in Cairo University Hospital Participants are adult patients (above \>40 years), (BMI \< 35) with American Society of Anesthesiologists physical status (ASA-PS) I-III, scheduled for elective surgery under general anesthesia with tracheal intubation . Exclusion criteria included patients with history of difficult intubation or apparent airway abnormalities (facial scars, neck scars, unstable cervical spine and history of cervical spine fixation) that would require alternative technique other than endotracheal intubation with direct laryngoscopy. Also, edentulous patients, patients undergoing emergency procedure and pregnant women are excluded from the study. Hypothesis The investigators hypothesize that combined class 3 ULBT and DSE \>2 cm can accurately predict difficult laryngoscopy in adult patients undergoing elective procedure under general anesthesia with endotracheal intubation.


Eligibility Criteria:
Inclusion Criteria:

* Participants will be adult patients (above \>40 years) ( BMI \< 35) with ASA-PS I-III, scheduled for elective surgery under general anesthesia with tracheal intubation.

Exclusion Criteria:

* Patients with history of difficult intubation or apparent airway abnormalities (facial scars, neck scars, unstable cervical spine and history of cervical spine fixation) that would require alternative technique other than endotracheal intubation.

Edentulous patients patients undergoing emergency procedure pregnant women were excluded from the study.
Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma

To explore PFS, ORR (CR/CRu+PR), OS and side effects of piamprizumab combined with RMA in newly diagnosed PCNSL, so as to clarify the value of piamprizumab combined with RMA in the first-line treatment of PCNSL patients, and to clarify the clinical and biological factors affecting the efficacy


Eligibility Criteria:
Inclusion Criteria:

* For initial PCNSL confirmed by pathological tissue, the diagnostic criteria were based on WHO diagnostic criteria in 2016
* Head MR (plain scan + enhancement) performed 28 days prior to study enrollment should show the presence of at least one measurable lesion in two vertical directions (according to 2014 Lugano criteria); Or abnormal cerebrospinal fluid examination (including cerebrospinal fluid protein, cells, NGS), or ophthalmologic examination confirmed the retina, vitreous lesions
* PS score was 0\~4 according to ECOG

Exclusion Criteria:

* Organs or lymph nodes outside the central nervous system are involved
* Patients with a second primary tumor (other than non-melanoma skin cancer in situ, superficial bladder cancer, cervical cancer in situ, gastrointestinal intramucosal cancer or breast cancer that has been cured and has not recurred within 5 years)
* Has a history of allergic disease, severe drug allergy, or is known to be allergic to any component of a macromolecular protein preparation or penpulimab injection prescription
* Prior treatment with anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CTLA-4 antibody, or CAR T cell therapy (or any other antibody that acts on T cell co-stimulation or checkpoint pathways)
* A severe acute or chronic infection requiring systemic treatment
* The investigator believes that the subjects may have other factors that affect the efficacy or safety evaluation of the study